Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ImSAF
- Development stage
- Discontinued
- Lead developer
- VG Life Sciences
- Modality
- Peptides
- Administration
- Topical
01
Overview
ImSAF (Immunological Skin and Autoimmune Formula) is a topical immunomodulator developed by VG Life Sciences (formerly Viral Genetics) for the treatment of autoimmune and inflammatory skin conditions. The therapy was designed to modulate local immune responses in the skin, leveraging the company's research into peptide-based immune regulation. VG Life Sciences' core technology involved 'Targeted Peptides' that aimed to influence the MHC Class II antigen-associated invariant chain (Ii) to redirect the immune system and alleviate inflammation. Development of ImSAF has ceased following the company's transition out of the biotechnology sector and the abandonment of its pharmaceutical pipeline.
- Other names
- Immunological Skin and Autoimmune Formula
02
Targets
CLIP (Class II-associated invariant chain peptide)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on ImSAF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImSAF.